Trends in Bioprocessing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Trends in Bioprocessing
The second annual Pharmaceutical Technology Bioprocessing Survey offers a snapshot of the industry following 2009's megamergers.This article contains online-exclusive bonus material.

Pharmaceutical Technology
Volume 34


Figure 10: Vaccine production systems used by respondents.
We asked respondents to tell us about the innovations that have most improved their processes in the past year, and what they hope to see in the future. Respondents said that disposables in various forms had improved their processes. Single-use sensors, bioreactors, chromatography columns, and filters were mentioned repeatedly. Respondents look forward to more improvements and innovations in single-use technologies to enhance product quality and process efficiencies. In addition, they are looking for manufacturers to create analytics that can discern the disposition of glycans on proteins and processes that allow better control of protein glycosylation, better contamination identification and detection methods, improvements in affinity resins for protein purification, improvements in cell-based expression systems, and improved analytics for determining protein structural information.

Survey Participants

Figure 11: Biopharmaceutical manufacturing focus of respondents (multiple answers allowed).
Three-hundred-and-eighty-four respondents completed the survey this year. About 79% were male, aged 45 on average, and represented an average number of 17 years professional experience. At 48%, the largest number come from the United States (including Puerto Rico), followed by 26% from Western Europe, 7% from India, 6% from Asia other than India or China, and 2% from Canada. Thirty-one percent indicated their companies were innovator pharmaceutical companies producing branded drugs, 28% were from biotech companies, 10% were from contract manufacturers, and 7% were from generic companies. The rest represent consultants, consumer healthcare companies and suppliers of raw materials, equipment and machinery. About 20% are in research, and another 19% are in process development. Sixteen percent are in production management, 14% are in quality assurance and control and 5% are concerned with regulatory affairs. The remainder are consultants or perform some other job function. Their companies' average revenue is $10 billion.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here